JP2002531524A5 - - Google Patents

Download PDF

Info

Publication number
JP2002531524A5
JP2002531524A5 JP2000586365A JP2000586365A JP2002531524A5 JP 2002531524 A5 JP2002531524 A5 JP 2002531524A5 JP 2000586365 A JP2000586365 A JP 2000586365A JP 2000586365 A JP2000586365 A JP 2000586365A JP 2002531524 A5 JP2002531524 A5 JP 2002531524A5
Authority
JP
Japan
Prior art keywords
cancer cells
composition
cancer
chemotherapeutic agent
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000586365A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002531524A (ja
JP4380922B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA1999/001157 external-priority patent/WO2000033875A1/en
Publication of JP2002531524A publication Critical patent/JP2002531524A/ja
Publication of JP2002531524A5 publication Critical patent/JP2002531524A5/ja
Application granted granted Critical
Publication of JP4380922B2 publication Critical patent/JP4380922B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

JP2000586365A 1998-12-04 1999-12-03 化学療法の組成物及び方法 Expired - Fee Related JP4380922B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11101998P 1998-12-04 1998-12-04
US60/111,019 1998-12-04
US12732099P 1999-04-01 1999-04-01
US60/127,320 1999-04-01
PCT/CA1999/001157 WO2000033875A1 (en) 1998-12-04 1999-12-03 Chemotherapeutic composition and method

Publications (3)

Publication Number Publication Date
JP2002531524A JP2002531524A (ja) 2002-09-24
JP2002531524A5 true JP2002531524A5 (https=) 2008-07-31
JP4380922B2 JP4380922B2 (ja) 2009-12-09

Family

ID=26808584

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000586365A Expired - Fee Related JP4380922B2 (ja) 1998-12-04 1999-12-03 化学療法の組成物及び方法

Country Status (11)

Country Link
EP (1) EP1135161B1 (https=)
JP (1) JP4380922B2 (https=)
AT (1) ATE276766T1 (https=)
AU (1) AU782335B2 (https=)
CA (1) CA2353905C (https=)
DE (1) DE69920506T2 (https=)
DK (1) DK1135161T3 (https=)
ES (1) ES2229792T3 (https=)
NZ (1) NZ511941A (https=)
PT (1) PT1135161E (https=)
WO (1) WO2000033875A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794368B1 (en) 1999-04-01 2004-09-21 Bioniche Life Sciences Inc. Composition and method for inducing apoptosis in prostate cancer cells
CA2395493C (en) 1999-12-28 2010-06-22 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer
CN105943559A (zh) * 2010-10-13 2016-09-21 特莱斯塔治疗知识产权公司 细菌核糖核酸细胞壁组合物及其制备和使用方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100533576B1 (ko) * 1997-08-05 2005-12-05 바이오니취 라이프 사이언시즈 인코포레이티드 세포증식 및 세포사멸 조절용 조성물 및 방법

Similar Documents

Publication Publication Date Title
Tribble Antibiotic therapy for acute watery diarrhea and dysentery
Peloquin Using therapeutic drug monitoring to dose the antimycobacterial drugs
Lü et al. Homoharringtonine and omacetaxine for myeloid hematological malignancies
Labana et al. Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes
Belani et al. Etoposide: current status and future perspectives in the management of malignant neoplasms
Pandey et al. Nanoparticle-based oral drug delivery system for an injectable antibiotic–streptomycin: evaluation in a murine tuberculosis model
JP2006515883A5 (https=)
CA2401191C (en) A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
Sawas et al. A phase 1 study of the anti-CD37 antibody-drug conjugate AGS67E in advanced lymphoid malignancies. Interim results
Singh et al. Molecular mechanisms of drug resistance in Mycobacterium tuberculosis: Role of nanoparticles against multi-drug-resistant tuberculosis (MDR-TB)
Kumar et al. The shifting therapeutic paradigm for relapsed/refractory mantle cell lymphoma
Eldin et al. A novel synergistic enzyme-antibiotic therapy with immobilization of mycobacteriophage Lysin B enzyme onto Rif@ UiO-66 nanocomposite for enhanced inhaled anti-TB therapy; Nanoenzybiotics approach
JP2002531524A5 (https=)
MX2007006646A (es) Metodos para administrar inhibidores de dihidropirimidina deshidrogenasa en combinacion con 5-fluorouracilo y profarmacos de 5-fluorouracilo.
Benson III et al. Optimal use of the combination of irinotecan and 5-fluorouracil
Weide Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin’s lymphoma
Saotome et al. Combination chemotherapy with irinotecan and adriamycin for refractory and relapsed non-Hodgkin's lymphoma
Drews Immunostimulation: Clinical and experimental perspectives
JP2002541114A5 (https=)
Owonikoko et al. E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer
Gupta et al. Mechanisms of Drug Resistance in Tuberculosis and Potential Modulation Strategies
de Lima Lopes Jr et al. Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors: preliminary evidence of activity in small cell and neuroendocrine carcinomas
Rose et al. Phase II trial of 4′ deoxydoxorubicin (DXDX) for unresectable non-small cell bronchogenic carcinoma: An Illinois Cancer Council Study
Furuse CPT-11 in the treatment of small-cell lung cancer
Pinter-Brown et al. Safety and Management of Pralatrexate Treatment in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL).